Institute of Pharmacy, Martin-Luther-Universität Halle-Wittenberg, 06120 Halle, Germany.
Bioorg Med Chem. 2010 Mar 1;18(5):1816-21. doi: 10.1016/j.bmc.2010.01.053. Epub 2010 Jan 25.
A series of novel small molecules with a 1,2,4-triazine scaffold was obtained according to a recently published and highly efficient synthetic route. Screening for antiproliferative and cytotoxic activity revealed distinct anticancer effects against the human leukemia cell line K-562 combined with a remarkable low cytotoxicity. All compounds were in agreement with the 'rule-of-five' claims by Lipinski and calculated logP(calc) values were experimentally confirmed (logP(exp)). For the most active compounds, in vitro serum albumin binding was investigated and structure-activity relationships were established.
根据最近发表的一种高效合成路线，获得了一系列具有 1,2,4-三嗪骨架的新型小分子。对增殖抑制和细胞毒性活性的筛选显示，这些化合物对人白血病细胞系 K-562 具有明显的抗癌作用，同时具有显著的低细胞毒性。所有化合物均符合 Lipinski 的“五规则”要求，计算的 logP(calc) 值得到了实验验证（logP(exp)）。对最活跃的化合物进行了体外血清白蛋白结合的研究，并建立了构效关系。
